Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n
Action and use<\/strong><\/p>\n Angiotensin converting enzyme inhibitor.<\/p>\n Preparation<\/strong><\/p>\n Quinapril Tablets Ph Eur<\/p>\n (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride.<\/p>\n Content<\/strong><\/p>\n 98.5 per cent to 101.5 per cent (anhydrous substance).<\/p>\n White or almost white or slightly pink, hygroscopic powder.<\/p>\n Freely soluble in water and in ethanol (96 per cent), very slightly soluble in acetone.<\/p>\n A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n Comparison\u00a0 quinapril hydrochloride CRS.<\/p>\n B. Specific optical rotation (see Tests).<\/p>\n C. It gives reaction (a) of chlorides (2.3.1).<\/p>\n Specific optical rotation (2.2.7)<\/p>\n + 14.4 to + 16.6 (anhydrous substance).<\/p>\n Dissolve 0.500 g in methanol R and dilute to 25.0 mL with the same solvent.<\/p>\n Liquid chromatography (2.2.29). Prepare the solutions immediately before use.<\/p>\n Solvent mixture\u00a0 Adjust 500 mL of the mobile phase to pH 6.5 with concentrated ammonia R.<\/p>\n Test solution Dissolve 100 mg of the substance to be examined in the solvent mixture and dilute to 50.0 mL with the solvent mixture.<\/p>\n Reference solution (a) Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 20.0 mL with the solvent mixture.<\/p>\n Reference solution (b) Dissolve the contents of a vial of quinapril for peak identification CRS (containing impurities G, H and I) in the solvent mixture and dilute to 5.0 mL with the solvent mixture.<\/p>\n Column:<\/p>\n \u2014 size: l = 0.25 m, \u00d8 = 4.0 mm;<\/p>\n \u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u00b5m);<\/p>\n \u2014 temperature: 25 \u00b0C.<\/p>\n Mobile phase\u00a0 Mix 260 mL of tetrahydrofuran R (non-stabilised) with 740 mL of a freshly prepared solution containing 1.08 g\/L of sodium octanesulfonate R and 2.88 g\/L of ammonium dihydrogen phosphate R, previously adjusted to pH 4.5 with phosphoric acid R.<\/p>\n Flow rate\u00a0 1.0 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 220 nm.<\/p>\n Injection\u00a0 20 \u00b5L.<\/p>\n Run time\u00a0 3.5 times the retention time of quinapril.<\/p>\n Identification of impurities Use the chromatogram supplied with quinapril for peak identification CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities G, H and I.<\/p>\n Relative retention With reference to quinapril (retention time = about 18 min): impurity G = about 0.9; impurity H = about 1.2; impurity I = about 1.3.<\/p>\n System suitability\u00a0 Reference solution (b):<\/p>\n \u2014 resolution: minimum 1.5 between the peaks due to impurity G and quinapril;<\/p>\n \u2014 peak-to-valley ratio: minimum 2.0, where Hp = height above the baseline of the peak due to impurity H and<\/p>\n Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to quinapril.<\/p>\n Limits:<\/p>\n \u2014 impurities G, H, I: for each impurity, not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent).<\/p>\n Liquid chromatography (2.2.29).<\/p>\n Solvent mixture Mix 40 volumes of acetonitrile R1 and 60 volumes of a 2.88 g\/L solution of ammonium dihydrogen phosphate R previously adjusted to pH 6.5 with dilute ammonia R1.<\/p>\n Test solution Dissolve 50 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.<\/p>\n Reference solution (a) Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.<\/p>\n Reference solution (b) Dissolve the contents of a vial of quinapril for system suitability CRS (containing impurities A, C, D, E and G) in the solvent mixture and dilute to 5.0 mL with the solvent mixture.<\/p>\n Reference solution (c)\u00a0 In order to prepare impurity M in situ, dissolve 250 mg of the substance to be examined in methylene chloride R and dilute to 5.0 mL with the same solvent. Expose this solution to a source of ultraviolet light for 2.5 h and evaporate the solvent. Dissolve 40 mg of the remaining substance in the solvent mixture and dilute to 20.0 mL with the solvent mixture.<\/p>\n Column:<\/p>\n \u2014 size: l = 0.15 m, \u00d8 = 3.9 mm;<\/p>\n \u2014 stationary phase: end-capped octylsilyl silica gel for chromatography R (5 \u00b5m).<\/p>\n Temperature:<\/p>\n \u2014 column: 30 \u00b0C;<\/p>\n \u2014 autosampler: 5 \u00b0C.<\/p>\n Mobile phase\u00a0 acetonitrile R1, 5.77 g\/L solution of sodium dodecyl sulfate R adjusted to pH 2.2 with phosphoric acid R (48:52 V\/V).<\/p>\n Flow rate\u00a0 1.4 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 214 nm.<\/p>\n Injection\u00a0 10 \u00b5L.<\/p>\n Run time\u00a0 3 times the retention time of quinapril.<\/p>\n Identification of impurities Use the chromatogram supplied with quinapril for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, C, D, E and G; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity M.<\/p>\n Relative retention With reference to quinapril (retention time = about 12 min): impurity A = about 0.1; impurity C = about 0.3; impurity D = about 0.4; impurity M = about 0.7; impurities G + H = about 0.9; impurity E = about 2.3.<\/p>\n System suitability\u00a0 Reference solution (b):<\/p>\n \u2014 resolution: minimum 1.5 between the peaks due to impurities C and D; minimum 1.5 between the peaks due to impurity G and quinapril.<\/p>\n Limits:<\/p>\n \u2014 correction factor: for the calculation of content, multiply the peak area of impurity E by 1.5;<\/p>\n \u2014 impurities C, D: for each impurity, not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);<\/p>\n \u2014 impurity A: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);<\/p>\n \u2014 impurities E, M: for each impurity, not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent);<\/p>\n \u2014 unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);<\/p>\n \u2014 total: not more than 10 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent);<\/p>\n \u2014 disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent); disregard any peak due to impurities G + H.<\/p>\n Maximum 1.0 per cent, determined on 0.500 g.<\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n Dissolve 0.200 g in 50 mL of water R. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20).<\/p>\n 1 mL of 0.1 M sodium hydroxide is equivalent to 23.75 mg of C25<\/sub>H31<\/sub>ClN2<\/sub>O5<\/sub>.<\/p>\n In an airtight container at a temperature of 2 \u00b0C to 8 \u00b0C.<\/p>\n Specified impurities\u00a0 A, C, D, E, G, H, I, M.<\/em><\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, J.<\/em><\/p>\n A. (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,<\/p>\n B. (2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoic acid,<\/p>\n C. (3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,<\/p>\n D. ethyl (2S)-2-[(3S,11aS)-3-methyl-1,4-dioxo-1,3,4,6,11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinolin-2-yl]-4- phenylbutanoate,<\/p>\n E. (3S)-2-[(2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3- carboxylic acid,<\/p>\n G. (3R)-2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic\u00a0 acid,<\/p>\n H. (3R)-2-[(2S)-2-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic\u00a0 acid,<\/p>\n I. (3S)-2-[(2S)-2-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic\u00a0 acid,<\/p>\n J. (1R,3S)-2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl](hydroxy)amino]propanoyl]-1-hydroxy-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid,<\/p>\n M. (1R,3S)-2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]-1-hydroperoxy-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Angiotensin converting enzyme inhibitor. Preparation Quinapril Tablets Ph Eur DEFINITION (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride. Content 98.5 per cent to 101.5 per cent (anhydrous substance). CHARACTERS Appearance White or almost white or slightly pink, hygroscopic powder. Solubility Freely soluble in water and in ethanol (96 per cent),…<\/p>\n","protected":false},"author":5,"featured_media":28763,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-28762","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/28762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=28762"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/28762\/revisions"}],"predecessor-version":[{"id":28770,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/28762\/revisions\/28770"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/28763"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=28762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=28762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=28762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
Solubility<\/h3>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Diastereoisomers<\/h3>\n
Related substances<\/h3>\n
Water (2.5.12)<\/h4>\n
Sulfated ash (2.4.14)<\/h4>\n
ASSAY<\/h2>\n
STORAGE<\/h2>\n
IMPURITIES<\/h2>\n